Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007)
- PMID: 20067390
- DOI: 10.1086/647940
Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007)
Abstract
Background: The rationale and lessons learned through the evolution of the National Survey for the Susceptibility of Bacteroides fragilis Group from its initiation in 1981 through 2007 are reviewed here. The survey was conceived in 1980 to track emerging antimicrobial resistance in Bacteroides species.
Methods: Data from the last 11 years of the survey (1997-2007), including 6574 isolates from 13 medical centers, were analyzed for in vitro antimicrobial resistance to both frequently used and newly developed anti-anaerobic agents. The minimum inhibitory concentrations of the antibiotics were determined using agar dilution in accordance with Clinical and Laboratory Standards Institute recommendations.
Results: The analyses revealed that the carbapenems (imipenem, meropenem, ertapenem, and doripenem) and piperacillin-tazobactam were the most active agents against these pathogens, with resistance rates of 0.9%-2.3%. In the most recent 3 years of the survey (2005-2007), resistance to some agents was shown to depend on the species, such as ampicillin-sulbactam against Bacteroides distasonis (20.6%) and tigecycline against Bacteroides uniformis and Bacteroides eggerthii ( approximately 7%). Very high resistance rates (>50%) were noted for moxifloxacin and trovafloxacin, particularly against Bacteroides vulgatus. During that period of study, non-B. fragilis Bacteroides species had >40% resistance to clindamycin. Metronidazole-resistant Bacteroides strains were also first reported during that period.
Conclusions: In summary, resistance to antibiotics was greater among non-B. fragilis Bacteroides species than among B. fragilis and was especially greater among species with a low frequency of isolation, such as Bacteroides caccae and B. uniformis. The emergence of resistance among the non-B. fragilis Bacteroides species underscores the need for speciation of B. fragilis group isolates and for clinicians to be aware of associations between species and drug resistance.
Similar articles
-
Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.Rev Argent Microbiol. 2007 Jul-Sep;39(3):156-60. Rev Argent Microbiol. 2007. PMID: 17987852
-
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.Antimicrob Agents Chemother. 2007 May;51(5):1649-55. doi: 10.1128/AAC.01435-06. Epub 2007 Feb 5. Antimicrob Agents Chemother. 2007. PMID: 17283189 Free PMC article.
-
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.Antimicrob Agents Chemother. 2008 Dec;52(12):4492-6. doi: 10.1128/AAC.00696-08. Epub 2008 Oct 6. Antimicrob Agents Chemother. 2008. PMID: 18838581 Free PMC article.
-
Newer beta-lactam agents and the Bacteroides fragilis group.Pharmacotherapy. 1991;11(2 ( Pt 2)):51S-55S. Pharmacotherapy. 1991. PMID: 2041832 Review.
-
Antimicrobial susceptibility testing of anaerobic bacteria.Rev Infect Dis. 1984 Mar-Apr;6 Suppl 1:S242-8. doi: 10.1093/clinids/6.supplement_1.s242. Rev Infect Dis. 1984. PMID: 6372033 Review.
Cited by
-
Identification of a collagen type I adhesin of Bacteroides fragilis.PLoS One. 2014 Mar 11;9(3):e91141. doi: 10.1371/journal.pone.0091141. eCollection 2014. PLoS One. 2014. PMID: 24618940 Free PMC article.
-
Recovery of the gut microbiome following enteric infection and persistence of antimicrobial resistance genes in specific microbial hosts.Sci Rep. 2023 Sep 19;13(1):15524. doi: 10.1038/s41598-023-42822-7. Sci Rep. 2023. PMID: 37726374 Free PMC article.
-
Multicenter study of antimicrobial susceptibility of anaerobic bacteria in Korea in 2012.Ann Lab Med. 2015 Sep;35(5):479-86. doi: 10.3343/alm.2015.35.5.479. Ann Lab Med. 2015. PMID: 26206683 Free PMC article.
-
In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species.Antimicrob Agents Chemother. 2016 Sep 23;60(10):6393-7. doi: 10.1128/AAC.01125-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27480858 Free PMC article.
-
Antibiotic Resistance and Mechanisms of Pathogenic Bacteria in Tubo-Ovarian Abscess.Front Cell Infect Microbiol. 2022 Jul 27;12:958210. doi: 10.3389/fcimb.2022.958210. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35967860 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical